Lipocine announces positive lpcn 2401 clinical results showing improved body composition in participants with obesity

Lpcn 2401 treatment resulted in statistically significant body composition improvement in men increased lean mass (lm) by 4.4% and decreased fat mass (fm) by 6.7% reduced android fat (af) by 4.1% and increased bone mineral content (bmc) by 2.8% well-tolerated, adverse events (aes) similar to placebo potential for use in combination with incretin mimetics (glp-1/gip agonists and/or post glp-1/gip agonist) or as a monotherapy post discontinuation conference call and webcast at 8.30 a.m. et today salt lake city , april 11, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company, today announced results from a phase 2 clinical trial (nct04134091) which includes lpcn 2401, an oral proprietary combination of anabolic androgen receptor agonist and Α-tocopherol, an antioxidant.
LPCN Ratings Summary
LPCN Quant Ranking